Australia markets close in 1 hour 48 minutes

Allakos Inc. (ALLK)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
1.4400-0.0100 (-0.69%)
At close: 04:00PM EDT
1.4600 +0.02 (+1.39%)
After hours: 06:59PM EDT

Allakos Inc.

825 Industrial Road
Suite 500
San Carlos, CA 94070
United States
650 597 5002
https://www.allakos.com

Sector(s)Healthcare
IndustryBiotechnology
Full-time employees131

Key executives

NameTitlePayExercisedYear born
Dr. Robert Alexander Ph.D.CEO & Director1.5MN/A1970
Dr. Adam L. Tomasi Ph.D.President1.15MN/A1970
Mr. Baird Radford IIIChief Financial Officer731.35kN/A1970
Ms. Mary Cromwell Ph.D.Chief Technical OfficerN/AN/AN/A
Dr. Chin Lee M.D., M.P.H.Chief Medical OfficerN/AN/A1970
Mr. Alan ChangDirector of Medical Affairs & Data AnalyticsN/AN/AN/A
Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Allakos Inc., a clinical stage biotechnology company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases in the United States. The company's lead product candidate is AK006, which in a Phase I clinical trial for the treatment of chronic spontaneous urticaria (CSU) and other indications. The company was incorporated in 2012 and is headquartered in San Carlos, California.

Corporate governance

Allakos Inc.’s ISS governance QualityScore as of 1 May 2024 is 9. The pillar scores are Audit: 5; Board: 10; Shareholder rights: 8; Compensation: 10.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.